Stayble presents Q3 report in webcast
Stayble and FinWire host the event on 19 November at 13:00.
See the latest news and media coverage for Stayble. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biopharmaceutical company
staybletherapeutics.comLast updated
In short: Stayble Therapeutics filed for bankruptcy following severe financial difficulties and a lack of revenue, leading to a suspension of its shares.
Stayble and FinWire host the event on 19 November at 13:00.
The report summarizes costs of 3 948 KSEK, result -3 921 KSEK and progress for STA363 towards phase 2 trial. Share issue added 4.55 MSEK.
The company carries out directed issue, reduces costs and prepares STA363 for phase 2 study. Operating result improves to -3.9 MSEK.
The meeting approves the accounts for 2024, grants discharge of liability, re-elects the board of directors and auditor, resolves on fees and amends the articles of association. It was held on June 5, 2025.
After financing problems, the Gothenburg company is now applying for bankruptcy on its own request. The background is about lack of revenue, explains the bankruptcy administrator.
Close Alleima inaugurates new pipe mill in Sandviken: 'A milestone'. Most consumers look at the electricity bill and see a single amount. But what does it really consist of...
Erik Kinnman leaves the board of Stayble Therapeutics, at his own request and with immediate effect.
Stayble Therapeutics continues to drive its business forward. An extraordinary general meeting on Thursday said no to putting the company into liquidation. At the same time, board member Erik...
Track Stayble and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.